HilleVax reports Q4 EPS (56c), consensus ($1.46)

"2022 was a momentous year for HilleVax where the company achieved many important milestones including the initiation and execution of our Phase 2b clinical trial NEST-IN1 and the completion of our initial public offering," said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. "We look forward to completing enrollment of our NEST-IN1 clinical trial in 2023 and announcing top line safety and clinical efficacy data in the first quarter of 2024."